Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)Jonathan Choi2023-01-26T15:01:39+00:00December 2nd, 2022|Featured, Our Publications|
Chemical M&A trends shift down (ICIS Chemical Business August 26 – September 1, 2022)digitalstudios2022-08-28T14:56:04+00:00August 26th, 2022|Featured|
Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)digitalstudios2022-08-12T18:23:33+00:00August 12th, 2022|Featured|
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)Devin Maraj2022-04-12T16:14:36+00:00April 12th, 2022|Featured, Our Publications|
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)Devin Maraj2022-03-12T02:24:09+00:00March 11th, 2022|Featured, Our Publications|
Pharm Exec: China Invests in Building Biotech (Young & Partners comments – January 2022)Devin Maraj2022-03-01T15:13:27+00:00March 1st, 2022|Our Publications|
Chemicals M&A to be resilient in 2022 (ICIS Chemical Business February 11 – February 17 2022)Devin Maraj2022-02-18T20:54:48+00:00February 18th, 2022|Featured, Our Publications|
New Supply Chains (ICIS Chemical Business November 26 – December 2 2021)Devin Maraj2021-12-03T19:56:38+00:00December 3rd, 2021|Featured, Our Publications|
Chemical Economic, M&A and Financing (ICIS Chemical Business November 19-26 2021)Devin Maraj2021-11-22T17:29:34+00:00November 22nd, 2021|Featured, Our Publications|
Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)Devin Maraj2021-09-16T20:12:39+00:00September 16th, 2021|Featured, Our Publications|
